MESA LABORATORIES INCMLABEarnings & Financial Report
Mesa Laboratories Inc. develops, manufactures and sells professional quality control, calibration and monitoring instruments as well as related supporting services. Its core offerings cater to healthcare, pharmaceutical, food and beverage, industrial hygiene and environmental testing markets, helping global clients meet regulatory compliance and operational safety requirements.
Revenue
$60.7M
Gross Profit
$37.3M
Operating Profit
$4.7M
Net Profit
$2.5M
Gross Margin
61.5%
Operating Margin
7.8%
Net Margin
4.1%
YoY Growth
5.0%
EPS
$0.45
MESA LABORATORIES INC Q2 FY2026 Financial Summary
MESA LABORATORIES INC reported revenue of $60.7M (up 5.0% YoY) for Q2 FY2026, with a net profit of $2.5M (down 27.8% YoY) (4.1% margin). Cost of goods sold was $23.4M, operating expenses totaled $32.6M.
Key Financial Metrics
| Total Revenue | $60.7M |
|---|---|
| Net Profit | $2.5M |
| Gross Margin | 61.5% |
| Operating Margin | 7.8% |
| Report Period | Q2 FY2026 |
Revenue Breakdown
MESA LABORATORIES INC Q2 FY2026 revenue of $60.7M breaks down across 4 segments, led by Sterilization And Disinfection Control at $22.1M (36.4% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Sterilization And Disinfection Control | $22.1M | 36.4% |
| Biopharmaceutical Development | $13.9M | 22.9% |
| Other | $13.6M | 22.3% |
| Clinical Genomics | $11.1M | 18.3% |
MESA LABORATORIES INC Revenue by Segment — Quarterly Trend
MESA LABORATORIES INC revenue by segment across the last 4 reported quarters, showing how each business line (such as Sterilization And Disinfection Control and Biopharmaceutical Development) has evolved quarter over quarter.
| Segment | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 |
|---|---|---|---|---|
| Sterilization And Disinfection Control | $24.9M | $22.1M | $25.4M | $24.7M |
| Biopharmaceutical Development | $14.4M | $13.9M | $11.5M | — |
| Other | $14.1M | $13.6M | — | — |
| Clinical Genomics | $11.8M | $11.1M | $10.3M | $11.5M |
MESA LABORATORIES INC Annual Revenue by Year
MESA LABORATORIES INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $241.0M).
| Year | Annual Revenue |
|---|---|
| 2025 | $241.0M |
| 2024 | $216.2M |
| 2023 | $219.1M |
| 2022 | $184.3M |
MESA LABORATORIES INC Quarterly Revenue & Net Profit History
MESA LABORATORIES INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2026 | $65.1M | +3.6% | $3.6M | 5.6% |
| Q2 FY2026 | $60.7M | +5.0% | $2.5M | 4.1% |
| Q1 FY2026 | $59.5M | +2.4% | $4.7M | 8.0% |
| Q4 FY2025 | $62.1M | +5.5% | $-7.1M | -11.4% |
| Q3 FY2025 | $62.8M | +17.5% | $-1.7M | -2.7% |
| Q2 FY2025 | $57.8M | +8.8% | $3.4M | 5.9% |
| Q1 FY2025 | $58.2M | +14.9% | $3.4M | 5.8% |
| Q4 FY2024 | $58.9M | +6.0% | $-254.6M | -432.2% |
Income Statement
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $58.9M | $58.2M | $57.8M | $62.8M | $62.1M | $59.5M | $60.7M | $65.1M |
| YoY Growth | 6.0% | 14.9% | 8.8% | 17.5% | 5.5% | 2.4% | 5.0% | 3.6% |
Balance Sheet
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $446.8M | $440.4M | $454.1M | $433.3M | $433.3M | $435.7M | $430.4M | $434.8M |
| Liabilities | $301.4M | $289.6M | $292.6M | $273.5M | $273.5M | $263.2M | $251.9M | $248.2M |
| Equity | $145.4M | $150.7M | $161.5M | $155.2M | $159.8M | $172.5M | $178.5M | $186.7M |
Cash Flow
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $12.9M | $10.7M | $5.3M | $18.1M | $12.7M | $1.9M | $8.2M | $18.8M |